Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies.

[1]  M. Welch,et al.  Preparation and evaluation of 17-ethynyl-substituted 16 alpha-[18F]fluoroestradiols: selective receptor-based PET imaging agents. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[2]  B. Van Den Bossche,et al.  Receptor imaging in oncology by means of nuclear medicine: current status. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Epperly,et al.  Radiotoxicity of 17α-[125I]iodovinyl-11β-methoxyestradiol in MCF-7 human breast cancer cells , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  M. Welch,et al.  Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M. Welch,et al.  16 alpha-[77Br]bromo-11 beta-methoxyestradiol-17 beta: a gamma-emitting estrogen imaging agent with high uptake and retention by target organs. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  J. Schwartz,et al.  Cellular and subcellular studies of the radiation effects of Auger electron-emitting estrogens. , 1996, Acta oncologica.

[7]  F. Diederich,et al.  Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.

[8]  C. Redmond,et al.  Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.

[9]  O. DeJesus,et al.  Bromine-80m-labeled estrogens: Auger electron-emitting, estrogen receptor-directed ligands with potential for therapy of estrogen receptor-positive cancers. , 1988, Cancer research.

[10]  M. Welch,et al.  16α-[77Br]Bromoestradiol-17β: A High Specific-Activity, Gamma-Emitting Tracer with Uptake in Rat Uterus and Induced Mammary Tumors , 1981 .

[11]  M J Welch,et al.  Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  William C. Eckelman,et al.  Receptor-Binding Radiotracers , 1982 .

[13]  M. Welch,et al.  Erratum: Preparation and evaluation of 17-ethynyl-substituted 16α-[18F]fluoroestradiols: selective receptor-based PET imaging agents (Nuclear Medicine and Biology - International Journal of Radiation Applications and instrumentation Part B (Vol.nr. 19) (363-374)) , 1992 .

[14]  L. Tang.  Radionuclide production and yields at Washington University School of Medicine. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[15]  M. Lippman,et al.  Specific cytotoxicity of 16 alpha-[125I]iodoestradiol for estrogen receptor-containing breast cancer cells. , 1982, Endocrinology.

[16]  B. Furr,et al.  The pharmacology and clinical uses of tamoxifen. , 1984, Pharmacology & therapeutics.

[17]  M. Welch,et al.  Comparative breast tumor imaging and comparative in vitro metabolism of 16α-[18F]Fluoroestradiol-17β and 16β-[18f]fluoromoxestrol in isolated hepatocytes , 1999 .

[18]  R. Söremark,et al.  Distribution of bromide in mice. An autoradiographic study with Br82 , 1960 .

[19]  J. Katzenellenbogen,et al.  An Efficient Route for the Preparation of a 21-Fluoro Progestin-16α,17α-Dioxolane, a High-Affinity Ligand for PET Imaging of the Progesterone Receptor , 2002 .

[20]  R. Schiff,et al.  Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. , 2005, Breast.

[21]  Michael J. Welch,et al.  Positron emission tomographic assessment of ”metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy , 1999, European Journal of Nuclear Medicine.

[22]  M. Welch,et al.  Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. , 1993, Journal of medicinal chemistry.

[23]  J. Cunningham,et al.  Relationship of Estrogen and Progesterone Receptors to Prognosis in Breast Cancer , 1988, Annals of surgery.

[24]  Adrian V. Lee,et al.  Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Horwitz,et al.  The structure and function of progesterone receptors in breast cancer. , 1987, Journal of steroid biochemistry.

[26]  M. Welch,et al.  16 alpha-[77Br]bromoestradiol-17 beta: a high specific-activity, gamma-emitting tracer with uptake in rat uterus and uterus and induced mammary tumors. , 1981, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  M. Welch,et al.  16β-[18F]fluoromoxestrol : a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors , 1993 .

[28]  M. Welch,et al.  Methodology for the synthesis and specific activity determination of 16α-[77Br]-Bromoestradiol-17 β and 16α-[77Br]-11 β-methoxyestradiol-17 β, Two estrogen receptor-binding radiopharmaceuticals , 1982 .

[29]  R. Hanson.  The influence of structure modification on the metabolic transformations of radiolabeled estrogen derivatives , 1992 .

[30]  M. Welch,et al.  Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. , 1995, Journal of medicinal chemistry.

[31]  F. Denat,et al.  An Easy One-Pot Synthesis of Group 14 C-Metallated 2 (or 3)-Furan- and Thiophenecarbaldehydes , 1992 .

[32]  S. Noguchi,et al.  Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time , 1988, Cancer.

[33]  W. Bloomer,et al.  [125I]iodotamoxifen cytotoxicity in cultured human (MCF-7) breast cancer cells. , 1989, Journal of steroid biochemistry.

[34]  M. Welch,et al.  Characterization of the uptake of 16α-([18F]fluoro)-17β-estradiol in DMBA-induced mammary tumors , 1987 .

[35]  M. Welch,et al.  11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. , 1990, Journal of medicinal chemistry.

[36]  M. Namer,et al.  Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. , 1980, Cancer research.

[37]  R. Hanson,et al.  Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose. , 1992, Cancer research.

[38]  M. Welch,et al.  16 alpha-[77Br]bromoestradiol: dosimetry and preliminary clinical studies. , 1982, Journal of Nuclear Medicine.

[39]  W. Bloomer,et al.  Cytotoxicity of Receptor-Mediated 16α[125I]Iodo-estradiol in Cultured MCF-7 Human Breast Cancer Cells , 1989 .

[40]  K. Go,et al.  Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. , 1994, Nuclear medicine and biology.

[41]  M. Welch,et al.  Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Beckmann,et al.  Breaks in DNA accompany estrogen-receptor-mediated cytotoxicity from 16 alpha[125I]iodo-17 beta-estradiol. , 1993, Journal of cancer research and clinical oncology.

[43]  Y. Erdi,et al.  Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer , 2004 .

[44]  R. Mach,et al.  Synthesis and evaluation of a bromine-76-labeled PPARgamma antagonist 2-bromo-5-nitro-N-phenylbenzamide. , 2006, Nuclear medicine and biology.

[45]  M. Welch,et al.  (2R*,3S*)-1-[125I]Iodo-2,3-bis(4-hydroxyphenyl)pentane ([125I]iodonorhexestrol) and (2R*,3S*)-1-[77Br]Bromo-2,3-bis(4-hydroxyphenyl)pentane ([77Br]bromonorhexestrol), two gamma-emitting estrogens that show receptor-mediated uptake by target tissues in vivo. , 1982, Journal of Medicinal Chemistry.

[46]  J. Schwartz,et al.  DNA and chromosome breaks induced by iodine-123-labeled estrogen in Chinese hamster ovary cells. , 1996, Radiation research.

[47]  A. Howell,et al.  Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. , 1987, Cancer research.

[48]  C. Dence,et al.  Positron tomographic assessment of androgen receptors in prostatic carcinoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[49]  M. Beckmann,et al.  Breaks in DNA accompany estrogen-receptor-mediated cytotoxicity from 16α[125I]iodo-17β-estradiol , 2005, Journal of Cancer Research and Clinical Oncology.

[50]  M. Welch,et al.  Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. , 1982, Radiation research.

[51]  R. Weichselbaum,et al.  Estrogen receptor‐mediated cytotoxicity using iodine‐125 , 1983, Journal of cellular biochemistry.